002030DAJYSZSE

Daan Gene Co., Ltd

达安基因

002030

Shenzhen Stock Exchange

BoardMain Board of Shenzhen Stock Exchange
IndustryPharmaceutical Manufacturing
ISINCNE000001KP1
ListedAugust 9, 2004
Websitewww.daangene.com
IR Emailweb@daangene.com
Phone(+86)20-32290789
Sourcecninfo.com.cn
AddressNo.19, Xiangshan Road, Science City, Hi-tech Zone, Guangzhou, Guangdong

Company Overview

Daan Gene Co., Ltd. is a biomedical high-tech enterprise listed on the Shenzhen Stock Exchange since 2004. The company specializes in molecular diagnostic technology, focusing on the development, production, and sales of clinical test reagents, instruments, and supporting consumables. Daan Gene's product offerings include a wide range of diagnostic tools based on molecular, immunological, biochemical, and point-of-care testing technologies, addressing areas such as infectious disease detection, precision medicine, and public health. The company's operations are structured around several key business lines, including PCR diagnostic products, sequencing series products, and chemiluminescence series products. Daan Gene has established a comprehensive diagnostic product portfolio and a robust R&D platform, which supports its innovation and product development efforts. The company is recognized as a leading player in the domestic molecular diagnostics industry, with a strong market presence through its diverse brands, including "Daan Gene," "Darui Bio," and "Zhongshan Bio." Its extensive distribution network and commitment to customer value further enhance its competitive position in the market.

AI-generated from company disclosures and CNInfo data.

Company Profile

1.R&D platform Based on independent innovation platform, the company has been building a research institute without walls. The company has built nucleic acid diagnosis platform, sequencing diagnosis platform, biochip platform, immunology diagnosis platform, cytology diagnosis platform, biochemical diagnosis platform and other emerging and advanced diagnosis technology platforms, forming a leading R&D platform in China. Over the years, it has undertaken a number of national, ministerial, provincial, municipal and other major specialized research project in the field of biotechnology. Meanwhile, the platform is also the pharmaceutical bioengineering research center of the Ministry of health National; local joint engineering laboratory; provincial and municipal technology R&D center. What's more, it has established a multi-level scientific research platform together with domestic and foreign scientific research institutions, universities, enterprises, and hospitals. 2.Industrialization platform Daan Gene is a leading enterprise in the domestic molecular diagnostics industry, with a comprehensive and efficient product development, registration, production, and quality control system. This has formed a self-developed, fully integrated, and leading domestic nucleic acid testing technology platform. Furthermore, after years of meticulous planning, the company has established a comprehensive and leading domestic diagnostic product portfolio, encompassing a wide range of products, including Quantitative PCR, Sequencing, Mass Spectrometry, Chemiluminescence, Immunosorbent Assay, ELISA, Colloidal Gold, Point-of-Care (POCT), and Biochemical products. Its instrument portfolio includes Real-Time Quantitative PCR analyzers, fully automated Nucleic Acid Detection and Analysis systems, Digital PCR instruments, Electro-chemical Gene Chip Detectors, High-Throughput Sequencers, Liquid Chromatography-Tandem Mass Spectrometry Systems, Fully Automated Chemiluminescence Immunoassay Analyzers, Fully Automated Biochemical Analyzers, and Fluorescence Immunochromatography Analyzers. The company's robust production capacity for reagents, instruments, and supporting consumables ensures the timely and high-quality delivery of its products to customers, fully meeting market demand. The company boasts a rich product portfolio. The company and its subsidiaries hold over 700 Class II and Class III medical device registration certificates and hundreds of invention patents. 3.Multi Brand platform The company already boasts a diverse product line, encompassing instruments and testing pipelines, with Daan Gene at its core, as well as Pathology products, Chemiluminescence Immunoassays, Time-of-Flight Mass Spectrometer (TRF), public health, infectious diseases, eugenics, precision medicine, blood screening, and scientific research services. In the domestic market, the company boasts the industry-leading "Daan Gene" brand, the market-leading "Darui Bio" brand, and the regionally dominant "Zhongshan Bio." In the field of biochemical immunoassays, the company is focusing on developing the "DaTai Bio" brand. By establishing and implementing a multi-brand, parallel, and specialized development strategy, the company has forged a strong market synergy, consolidating and enhancing its competitive edge in the Chinese diagnostics market. 4.Market network platform The company adheres to the philosophy of “market-oriented” and “creating value for customers”. The company has established DAAN Marketing System with its own characteristics, and work continuously to improve its operation through building win-win Sales Platform and National Network Service Platform. Currently, we have built Bases in every province to support the local marketing operation. The established three-level operation system, “headquarters-province-county Network’’, is a national business network with strong salesforce and efficient service covering the business field of products sales, diagnosis services and diagnostic technology services. At the same time, the company is accelerating the construction of its sales network in the international market. 5.Industrial chain development platform Focusing on clinical diagnosis technology and products, based on company's platform resources, adhering to the mode of promoting the development of industrial chain through industrial investment, according to the working principle of combining benefit and efficiency, promoting innovation and extending the company's industrial layout, the company has formed an advantage with strong industrial integration and expansion ability, and also consolidates its development prospects. 6.Cultural platform The company has implemented the company culture system, insisting its management concept of “simple, sunny, standardized, efficient and responsible”, making the concept of “sharing growth value” deeply rooted in every member. It is a solid philosophy for the goal of building a “Centennial DAAN GENE”.

49 announcements tracked· Last: July 21, 2026

Key Financials

Revenue¥149.4M
Net Profit-¥98.2M
ROE-1.39%
Debt Ratio12.81%
Monetary Funds¥512.4M
Receivables¥719.1M
Total Shares1.40bn

Announcements

49 totalCSV

Notes & Comments

Sign in to leave a comment or private note.

No notes or comments yet.